Literature DB >> 21543432

Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease.

L van Dussen1, P Lips, V E Everts, N Bravenboer, I D C Jansen, J E M Groener, M Maas, J A K Blokland, J M F G Aerts, C E M Hollak.   

Abstract

CONTEXT: Gaucher disease (GD) is a lysosomal storage disorder characterized by abundant presence of macrophages. Bone complications and low bone density are believed to arise from enhanced bone resorption mediated through macrophage-derived factors.
OBJECTIVE: The objective of the study was to investigate the relationship between bone turnover and bone complications in GD.
DESIGN: This was a retrospective cohort study and review of the literature. PATIENTS: Forty adult type I GD patients were included in the study. OUTCOME MEASURES: Levels of the bone-resorption marker, type 1 collagen C-terminal telopeptide, and two bone-formation markers, N-terminal propeptide of type 1 procollagen and osteocalcin, were investigated in relation to clinical bone disease, measures of overall disease severity, and imaging data representing bone marrow infiltration.
RESULTS: Osteocalcin was decreased in 50% of our patients (median 0.35 nmol/liter, normal 0.4-4.0), indicating a decrease of bone formation. Type 1 collagen C-terminal telopeptide and N-terminal propeptide of type 1 procollagen were within the normal range for most patients. Osteocalcin concentration was negatively correlated to measures of overall disease severity and positively correlated with imaging data (correlation coefficient 0.423; P = 0.025), suggesting a relation with disease severity. A review of the literature revealed variable outcomes on bone resorption markers but more consistent abnormalities in bone formation markers. Two of three reports conclude that bone-formation parameters increase in response to enzyme therapy, but none describes an effect on bone-resorption markers.
CONCLUSIONS: In contrast to earlier hypotheses, we propose that in GD patients, primarily a decrease in bone formation causes an imbalance in bone remodeling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21543432     DOI: 10.1210/jc.2011-0162

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease.

Authors:  Pramod K Mistry; Jun Liu; Li Sun; Wei-Lien Chuang; Tony Yuen; Ruhua Yang; Ping Lu; Kate Zhang; Jianhua Li; Joan Keutzer; Agnes Stachnik; Albert Mennone; James L Boyer; Dhanpat Jain; Roscoe O Brady; Maria I New; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

Review 2.  Evaluation of an imaging biomarker, Dixon quantitative chemical shift imaging, in Gaucher disease: lessons learned.

Authors:  L van Dussen; E M Akkerman; C E M Hollak; A J Nederveen; M Maas
Journal:  J Inherit Metab Dis       Date:  2014-06-13       Impact factor: 4.982

3.  Long-term response in biochemical markers of bone turnover during enzyme replacement therapy in a case-series of patients with Gaucher disease type I from Northern Greece.

Authors:  E Vargiami; M Dimitriadou; M Economou; A Christoforidis; D I Zafeiriou
Journal:  Hippokratia       Date:  2016 Apr-Jun       Impact factor: 0.471

4.  Quantitation of a Urinary Profile of Biomarkers in Gaucher Disease Type 1 Patients Using Tandem Mass Spectrometry.

Authors:  Iskren Menkovic; Michel Boutin; Abdulfatah Alayoubi; Filipa Curado; Peter Bauer; François E Mercier; Christiane Auray-Blais
Journal:  Diagnostics (Basel)       Date:  2022-06-08

5.  Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.

Authors:  L van Dussen; E J Hendriks; J E M Groener; R G Boot; C E M Hollak; J M F G Aerts
Journal:  J Inherit Metab Dis       Date:  2014-05-16       Impact factor: 4.982

6.  Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models.

Authors:  Gertjan Kramer; Wouter Wegdam; Wilma Donker-Koopman; Roelof Ottenhoff; Paulo Gaspar; Marri Verhoek; Jessica Nelson; Tanit Gabriel; Wouter Kallemeijn; Rolf G Boot; Jon D Laman; Johannes P C Vissers; Timothy Cox; Elena Pavlova; Mary Teresa Moran; Johannes M Aerts; Marco van Eijk
Journal:  FEBS Open Bio       Date:  2016-07-30       Impact factor: 2.693

7.  Bone turnover markers in patients with type 1 Gaucher disease.

Authors:  Gaetano Giuffrida; Maria Rocca Cingari; Nunziatina Parrinello; Alessandra Romano; Anna Triolo; Magda Franceschino; Francesco Di Raimondo
Journal:  Hematol Rep       Date:  2012-11-29

8.  Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients.

Authors:  Arndt Rolfs; Anne-Katrin Giese; Ulrike Grittner; Daniel Mascher; Deborah Elstein; Ari Zimran; Tobias Böttcher; Jan Lukas; Rayk Hübner; Uta Gölnitz; Anja Röhle; Ales Dudesek; Wolfgang Meyer; Matthias Wittstock; Hermann Mascher
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

9.  Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat.

Authors:  Ravi S Kamath; Elena Lukina; Nora Watman; Marta Dragosky; Gregory M Pastores; Elsa Avila Arreguin; Hanna Rosenbaum; Ari Zimran; Rasha Aguzzi; Ana Cristina Puga; Andrea M Norfleet; M Judith Peterschmitt; Daniel I Rosenthal
Journal:  Skeletal Radiol       Date:  2014-05-10       Impact factor: 2.199

10.  Expression of CHI3L1 and CHIT1 in osteoarthritic rat cartilage model. A morphological study.

Authors:  M Di Rosa; M A Szychlinska; D Tibullo; L Malaguarnera; G Musumeci
Journal:  Eur J Histochem       Date:  2014-09-16       Impact factor: 3.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.